These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 29748183

  • 1. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P, Rühl J, Kannan A, Pircher M, Schuberth P, Nytko KJ, Pruschy M, Sulser S, Haefner M, Jensen S, Soltermann A, Jungraithmayr W, Eisenring M, Winder T, Samaras P, Tabor A, Stenger R, Stupp R, Weder W, Renner C, Münz C, Petrausch U.
    Clin Cancer Res; 2018 Aug 15; 24(16):3981-3993. PubMed ID: 29748183
    [Abstract] [Full Text] [Related]

  • 2. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells.
    Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzaran O, Stahel R, Renner C, Petrausch U.
    J Transl Med; 2013 Aug 12; 11():187. PubMed ID: 23937772
    [Abstract] [Full Text] [Related]

  • 3. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ.
    Blood; 2012 Jan 19; 119(3):696-706. PubMed ID: 22117050
    [Abstract] [Full Text] [Related]

  • 4. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
    Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.
    Clin Cancer Res; 2014 Aug 15; 20(16):4262-73. PubMed ID: 24919573
    [Abstract] [Full Text] [Related]

  • 5. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
    Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M.
    Sci Transl Med; 2014 Nov 05; 6(261):261ra151. PubMed ID: 25378643
    [Abstract] [Full Text] [Related]

  • 6. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
    Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C.
    BMC Cancer; 2012 Dec 22; 12():615. PubMed ID: 23259649
    [Abstract] [Full Text] [Related]

  • 7. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.
    Acharya S, Basar R, Daher M, Rafei H, Li P, Uprety N, Ensley E, Shanley M, Kumar B, Banerjee PP, Melo Garcia L, Lin P, Mohanty V, Kim KH, Jiang X, Pan Y, Li Y, Liu B, Nunez Cortes AK, Zhang C, Fathi M, Rezvan A, Montalvo MJ, Cha SL, Reyes-Silva F, Shrestha R, Guo X, Kundu K, Biederstädt A, Muniz-Feliciano L, Deyter GM, Kaplan M, Jiang XR, Liu E, Jain A, Roszik J, Fowlkes NW, Solis Soto LM, Raso MG, Khoury JD, Lin P, Vega F, Varadarajan N, Chen K, Marin D, Shpall EJ, Rezvani K.
    Cancer Discov; 2024 Oct 04; 14(10):1879-1900. PubMed ID: 38900051
    [Abstract] [Full Text] [Related]

  • 8. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.
    Cancer Lett; 2017 May 01; 393():52-59. PubMed ID: 28223167
    [Abstract] [Full Text] [Related]

  • 9. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun 01; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 10. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, Mutis T, Themeli M.
    Clin Cancer Res; 2019 Jul 01; 25(13):4014-4025. PubMed ID: 30979735
    [Abstract] [Full Text] [Related]

  • 11. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
    Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.
    J Clin Invest; 2016 Aug 01; 126(8):3130-44. PubMed ID: 27454297
    [Abstract] [Full Text] [Related]

  • 12. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
    Kofler DM, Chmielewski M, Rappl G, Hombach A, Riet T, Schmidt A, Hombach AA, Wendtner CM, Abken H.
    Mol Ther; 2011 Apr 01; 19(4):760-7. PubMed ID: 21326215
    [Abstract] [Full Text] [Related]

  • 13. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
    Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM.
    Cancer Immunol Res; 2014 Feb 01; 2(2):154-66. PubMed ID: 24778279
    [Abstract] [Full Text] [Related]

  • 14. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
    Yu Z, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NT, Man K, Liu L, Chen Z.
    Oncotarget; 2015 Oct 20; 6(32):32426-38. PubMed ID: 26431275
    [Abstract] [Full Text] [Related]

  • 15. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C, Shou P, Du H, Hirabayashi K, Chen Y, Herring LE, Ahn S, Xu Y, Suzuki K, Li G, Tsahouridis O, Su L, Savoldo B, Dotti G.
    Cancer Cell; 2020 Feb 10; 37(2):216-225.e6. PubMed ID: 32004441
    [Abstract] [Full Text] [Related]

  • 16. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, Han X, Wang P.
    Clin Cancer Res; 2017 Nov 15; 23(22):6982-6992. PubMed ID: 28912137
    [Abstract] [Full Text] [Related]

  • 17. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
    Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML.
    Cancer Immunol Res; 2021 Jan 15; 9(1):62-74. PubMed ID: 33188139
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells.
    Niu W, Wang B, Zhang Y, Wang C, Cao J, Li J, He Y, Lei P.
    Front Immunol; 2024 Jan 15; 15():1433679. PubMed ID: 39086477
    [Abstract] [Full Text] [Related]

  • 19. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.
    Clin Cancer Res; 2018 Jan 01; 24(1):95-105. PubMed ID: 29061641
    [Abstract] [Full Text] [Related]

  • 20. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS.
    Transl Res; 2017 Sep 01; 187():1-10. PubMed ID: 28502785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.